Showing 17–27 of 27 results
-
Add to cartAttribute Specification Product Name Mounjaro Bundles (Maintenance & Escalation Phase) Available Strengths 5mg / 0.5mL and 7.5mg / 0.5mL Active Ingredient Tirzepatide (Dual GIP and GLP-1 Receptor Agonist) Administration Route Subcutaneous Injection (Once-Weekly) Primary Indication Chronic Weight Management & Type 2 Diabetes Adjunct Packaging Configuration Multi-dose pre-filled injection pens (4-week supply per strength) Storage Requirements Refrigerated storage ($2^\circ\text{C}$ to $8^\circ\text{C}$), do not freeze -
Select options This product has multiple variants. The options may be chosen on the product pageProduct Characteristic Specification Details Active Ingredient Tirzepatide Therapeutic Class Dual GIP and GLP-1 Receptor Agonist Primary Indication Chronic Weight Management & Metabolic Support Administration Route Subcutaneous Injection (Once Weekly) Available Strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Storage Instructions Refrigerate between 2°C to 8°C; do not freeze -
Add to cartFeature Specification Product Name Mysimba Active Ingredients Naltrexone hydrochloride (8 mg) / Bupropion hydrochloride (90 mg) Dosage Form Prolonged-release tablets Primary Indication Chronic weight management in adults Mechanism Targets central nervous system pathways regulating food intake and energy expenditure Manufacturer Central Medical Supplies / Approved European Distributors -
Select options This product has multiple variants. The options may be chosen on the product pageThis is a variable product.
Etiam bibendum elit eget erat. Curabitur bibendum justo non orci. Cras elementum. In dapibus augue non sapien. Morbi imperdiet, mauris ac auctor dictum, nisl ligula egestas nulla, et sollicitudin sem purus in lacus. Praesent dapibus.
-
Select options This product has multiple variants. The options may be chosen on the product pageSpecification Details Product Name Orlistat 120mg Capsules Active Ingredient Orlistat (120mg) Therapeutic Class Peripherally Acting Anti-obesity Compound (Lipase Inhibitor) Primary Indication Clinical Obesity Management and Weight Reduction Mechanism of Action Inhibits gastric and pancreatic lipases to block 30% of dietary fat absorption Dosage Form Hard Gelatin Capsules Standard Dosage One capsule taken with water immediately before, during, or up to one hour after each main meal containing fat (Maximum 3 times daily) Target Population Adults with a BMI $\ge 30$, or BMI $\ge 28$ with associated risk factors (e.g., hypertension, type 2 diabetes) Shipping & Packaging Secure, patient-centric packaging with overnight discreet delivery -
Select options This product has multiple variants. The options may be chosen on the product page
This is a simple product.
Nulla pulvinar eleifend sem. Sed vel lectus. Donec odio tempus molestie, porttitor ut, iaculis quis, sem. Mauris metus. Curabitur vitae diam non enim vestibulum interdum. Aenean id metus id velit ullamcorper pulvinar. Etiam sapien elit, consequat eget, tristique non, venenatis quis, ante. Integer vulputate sem a nibh rutrum consequat.
-
Select options This product has multiple variants. The options may be chosen on the product pageSpecification Product Details Brand Name Wegovy Active Ingredient Semaglutide (GLP-1 Receptor Agonist) Administration Route Subcutaneous Injection (Once Weekly) Available Dosages 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg Primary Indication Chronic Weight Management / Obesity Treatment Storage Requirements Refrigerate at 2°C to 8°C (Do not freeze) Manufacturer Novo Nordisk
